Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
M M
MM
Smits
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
L
L
Tonneijck
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
M H A
MH
Muskiet
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
M
M
Diamant
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
M H H
MH
Kramer
Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
D L
DL
Cahen
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
D H
DH
van Raalte
D000368:Aged; D000681:Amylases / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000201:enzymology; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents; D008049:Lipase / Q000097:blood; D008875:Middle Aged; D010455:Peptides / Q000009:adverse effects* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014688:Venoms / Q000009:adverse effects* / Q000627:therapeutic use*; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide; D008049:Lipase; D000681:Amylases; D000097789:Glucagon-Like Peptide-1 Receptor Agonists